Back to Posters

Prevalence of Germline Mutations in Consecutive, Unselected Patients with Newly Diagnosed Adenocarcinoma of the Pancreas.

Date:
Saturday, May 6, 2017 12:00pm – 2:00pm
Conference:
DDW 2017
Authors:
A.J. Moser, Allan Tsung, Amer H. Zureikat, Arlene Colvin, Beth Dudley, Brigette Tippin Davis, Courtney Grosvenor, Cynthia Lim, Emily Dalton, Erkut Borazanci, Eve Karloski, Herbert J. Zeh, Holly Laduca, J. Wallis Marsh, Jill Dolinsky, Kenneth Lee, Lindsey Stobie, Mary Helen Black, Mary Linton Peters, Melissa E. Hogg, Nadine Tung, Randall Brand, Virginia Speare
  • Identifying mutation carriers may provide potential targets for personalized treatment with agents such as PARP and immune checkpoint inhibitors and allows for recognition of family members who may benefit from pancreatic and other cancer screening and prevention strategies.
  • 5.5% of newly diagnosed unselected patients carry pathogenic mutation in genes known to contribute to pancreatic cancer risk (APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53). This information will be updated in the poster presentation at DDW.
Abstract Poster